Source comparison
BPC-157 for Degenerative Disc Disease Research: Comparison
Rat annular puncture (2019, J Orthop Res) 10 µg/kg IP daily, 8 weeks Inflammatory cytokine levels, collagen II expression 40% reduction in IL-1β, 35% increase in collagen II mRNA Short study duration, single injury model, no mechanical testing Demonstrated ant
This comparison does not assign a generated winner or score.
- Rat annular puncture (2019, J Orthop Res)
- 10 µg/kg IP daily, 8 weeks
- Inflammatory cytokine levels, collagen II expression
- 40% reduction in IL-1β, 35% increase in collagen II mRNA
- Short study duration, single injury model, no mechanical testing
- Demonstrated anti-inflammatory and anabolic effects in acute injury. Long-term degeneration not modelled
- Rabbit compression model (2021, Eur Spine J)
- 10 µg/kg IP daily, 6 weeks
- Disc height index, T2 MRI signal, histological grading
- Maintained 78% disc height vs 54% control, higher proteoglycan retention
- Surgical injury model may not reflect gradual human degeneration, no functional assessment
- Strongest evidence for structural preservation in a validated preclinical model
- Human nucleus pulposus cell culture (2020, in vitro)
- 1–10 µg/mL culture medium, 48–72 hours
- FAK phosphorylation, gene expression (collagen II, aggrecan)
- 62% increase in FAK activity, upregulated ECM gene expression
- In vitro only. No systemic factors, immune response, or mechanical load
- Confirms mechanism at cellular level but lacks translational context
- Rat intradiscal injection (2022, Spine)
- 50 µg intradiscal, single dose post-injury
- Apoptosis markers, MMP-3 expression, disc hydration
- 47% reduction in apoptotic cells, 38% decrease in MMP-3 at 4 weeks
- Single-dose study, invasive delivery not practical for humans, small sample size
- Intradiscal delivery shows promise but requires repeated procedures. Not viable long-term
- BPC-157 shows consistent effects across models. Reduced inflammation, preserved disc structure, enhanced matrix synthesis. But every study shares the same limitation: no human clinical trial data, no validated dosing for systemic (subcutaneous) delivery, and no long-term safety or efficacy endpoints.